Mechanism of action of chemoprotective ursodeoxycholate in the azoxymethane model of rat colonic carcinogenesis: potential roles of protein kinase C-alpha, -beta II, and -zeta - PubMed (original) (raw)
. 1995 Nov 15;55(22):5257-64.
Affiliations
- PMID: 7585585
Mechanism of action of chemoprotective ursodeoxycholate in the azoxymethane model of rat colonic carcinogenesis: potential roles of protein kinase C-alpha, -beta II, and -zeta
R K Wali et al. Cancer Res. 1995.
Abstract
Several lines of evidence from our laboratory and others indicate that epigenetic alterations in protein kinase C (PKC) are involved in colonic carcinogenesis in both man and experimental animals. Furthermore, bile salts, known activators of PKC, have also been implicated in colonic tumor development. Recently, however, our laboratory has demonstrated that, whereas dietary cholic acid increased the occurrence of azoxymethane (AOM)-induced rat colonic tumors, ursodeoxycholic acid was associated with a significant protective effect. In the present studies, we therefore examined changes in PKC isoforms that accompanied AOM-induced tumor formation and investigated whether the chemopromotional and/or chemopreventional actions of these supplemental dietary bile salts involved changes in specific isoforms of PKC. Rats treated with vehicle (saline) or AOM and maintained on bile salt unsupplemented or supplemented diets were used to isolate control colonocytes and carcinogen-induced tumors, which were then subjected to subcellular fractionation. The homogenates and subcellular fractions were then probed for individual PKC isoforms by quantitative Western blotting using isoform-specific antibodies. Normal rat colonocytes expressed PKC-alpha, -beta II, -delta, -epilson, and -zeta. AOM, in unsupplemented or cholate-supplemented groups, caused significant down-regulation of PKC-alpha, -delta and -zeta and up-regulation of PKC-beta II, while increasing particulate PKC-alpha, -beta II, and -zeta in carcinogen-induced tumors compared to normal colonocytes. Dietary supplementation with ursodeoxycholic acid, in marked contrast to these groups, prevented the changes in the subcellular distributions of PKC-alpha, -beta II, and -zeta, and preserved the expression of PKC-zeta in AOM-induced tumors. These studies suggest that changes in specific isoforms of PKC (particularly, PKC-alpha, -beta II, -delta, and/or -zeta) are involved in colonic malignant transformation in the AOM model but do not account for the chemopromotional actions of cholic acid in this model. Furthermore, the ability of ursodeoxycholic acid to block AOM-induced increases in particulate PKC-alpha, -beta II, and -zeta, and/or inhibit down-regulation of PKC-zeta, may contribute to the chemopreventive effects of this bile acid.
Similar articles
- Chemoprevention of azoxymethane-induced colonic carcinogenesis by supplemental dietary ursodeoxycholic acid.
Earnest DL, Holubec H, Wali RK, Jolley CS, Bissonette M, Bhattacharyya AK, Roy H, Khare S, Brasitus TA. Earnest DL, et al. Cancer Res. 1994 Oct 1;54(19):5071-4. Cancer Res. 1994. PMID: 7923119 - Ursodeoxycholic acid and F(6)-D(3) inhibit aberrant crypt proliferation in the rat azoxymethane model of colon cancer: roles of cyclin D1 and E-cadherin.
Wali RK, Khare S, Tretiakova M, Cohen G, Nguyen L, Hart J, Wang J, Wen M, Ramaswamy A, Joseph L, Sitrin M, Brasitus T, Bissonnette M. Wali RK, et al. Cancer Epidemiol Biomarkers Prev. 2002 Dec;11(12):1653-62. Cancer Epidemiol Biomarkers Prev. 2002. PMID: 12496057 - The roles of specific isoforms of protein kinase C in growth control and human colon cancer.
Weinstein IB. Weinstein IB. Princess Takamatsu Symp. 1991;22:277-83. Princess Takamatsu Symp. 1991. PMID: 1844247 Review. - Retinal protein kinase C.
Wood JP, McCord RJ, Osborne NN. Wood JP, et al. Neurochem Int. 1997 Feb;30(2):119-36. doi: 10.1016/s0197-0186(96)00049-6. Neurochem Int. 1997. PMID: 9017660 Review.
Cited by
- Chemoprevention of N-methylnitrosourea-induced colon carcinogenesis by ursodeoxycholic acid-5-aminosalicylic acid conjugate in F344 rats.
Narisawa T, Fukaura Y, Takeba N, Nakai K. Narisawa T, et al. Jpn J Cancer Res. 2002 Feb;93(2):143-50. doi: 10.1111/j.1349-7006.2002.tb01252.x. Jpn J Cancer Res. 2002. PMID: 11856477 Free PMC article. - High-dose ursodeoxycholic acid is associated with the development of colorectal neoplasia in patients with ulcerative colitis and primary sclerosing cholangitis.
Eaton JE, Silveira MG, Pardi DS, Sinakos E, Kowdley KV, Luketic VA, Harrison ME, McCashland T, Befeler AS, Harnois D, Jorgensen R, Petz J, Lindor KD. Eaton JE, et al. Am J Gastroenterol. 2011 Sep;106(9):1638-45. doi: 10.1038/ajg.2011.156. Epub 2011 May 10. Am J Gastroenterol. 2011. PMID: 21556038 Free PMC article. Clinical Trial. - Overexpression of protein kinase C betaII induces colonic hyperproliferation and increased sensitivity to colon carcinogenesis.
Murray NR, Davidson LA, Chapkin RS, Clay Gustafson W, Schattenberg DG, Fields AP. Murray NR, et al. J Cell Biol. 1999 May 17;145(4):699-711. doi: 10.1083/jcb.145.4.699. J Cell Biol. 1999. PMID: 10330400 Free PMC article. - Update on inflammatory bowel disease in patients with primary sclerosing cholangitis.
Tsaitas C, Semertzidou A, Sinakos E. Tsaitas C, et al. World J Hepatol. 2014 Apr 27;6(4):178-87. doi: 10.4254/wjh.v6.i4.178. World J Hepatol. 2014. PMID: 24799986 Free PMC article. Review. - Sodium taurocholate inhibits intestinal adenoma formation in APCMin/+ mice, potentially through activation of the farnesoid X receptor.
Smith DL, Keshavan P, Avissar U, Ahmed K, Zucker SD. Smith DL, et al. Carcinogenesis. 2010 Jun;31(6):1100-9. doi: 10.1093/carcin/bgq050. Epub 2010 Mar 1. Carcinogenesis. 2010. PMID: 20194350 Free PMC article.